MedTrace Logo

Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors

NCT07364656 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2026-01-23

No results posted yet for this study

Summary

The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.

Conditions

  • Brugada Syndrome (BrS)
  • Breast Cancer Females
  • Colon Cancer
  • ECG Abnormalities
  • Autoantibodies Screening

Interventions

DIAGNOSTIC_TEST

ECG

These patients require an ECG to exclude the onset of arrhythmias.

Sponsors & Collaborators

  • IRCCS San Raffaele

    collaborator OTHER

  • IRCCS Policlinico S. Donato

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07364656 on ClinicalTrials.gov